Trials / Unknown
UnknownNCT04084626
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
A Clinical Trial of Programmed Cell Death Protein 1(PD1) Antibody and Lenalidomide as a Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis or Chronic Active EBV Infection(CAEBV)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 1 Year – 65 Years
- Healthy volunteers
- Not accepted
Summary
The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active EBV infection patients were selected as the main subjects to evaluate the effect of PD-1 antibody and lenalidomide regimens on ebv-dna and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD1 antibody | 2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years). |
| DRUG | lenalidomide | 5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14. |
Timeline
- Start date
- 2019-09-15
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
- First posted
- 2019-09-10
- Last updated
- 2022-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04084626. Inclusion in this directory is not an endorsement.